BioCorRx annual debt-to-assets ratio
2013
2014
2015
2016
2018
2019
2020
2021
2022
2023
2024
2025
BioCorRx's debt-to-assets ratio was 0.07 for fiscal 2025.
View full BioCorRx company overview| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.07 | −0.44 | −85.64% |
| 2024 | 2024-12-31 | 0.52 | 0.17 | +50.14% |
| 2023 | 2023-12-31 | 0.34 | 0.11 | +45.32% |
| 2022 | 2022-12-31 | 0.24 | −0.31 | −56.62% |
| 2021 | 2021-12-31 | 0.55 | 0.31 | +128.80% |
| 2020 | 2020-12-31 | 0.24 | 0.13 | +118.93% |
| 2019 | 2019-12-31 | 0.11 | −5.47 | −98.05% |
| 2018 | 2018-12-31 | 5.58 | — | — |
| 2016 | 2016-12-31 | 0.19 | −1.14 | −86.00% |
| 2015 | 2015-12-31 | 1.32 | 1.13 | +600.65% |
| 2014 | 2014-12-31 | 0.19 | −0.07 | −25.85% |
| 2013 | 2013-12-31 | 0.25 | — | — |
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.07 | 0.05 | +168.94% |
| Q1 2026 | 2026-03-31 | 0.06 | 0.04 | +129.44% |
| Q4 2025 | 2025-12-31 | 0.07 | −0.44 | −85.64% |
| Q3 2025 | 2025-09-30 | 0.02 | −0.30 | −93.06% |
| Q2 2025 | 2025-06-30 | 0.03 | −0.35 | −92.84% |
| Q1 2025 | 2025-03-31 | 0.03 | 0.03 | — |
| Q4 2024 | 2024-12-31 | 0.52 | 0.17 | +50.14% |
| Q3 2024 | 2024-09-30 | 0.32 | 0.19 | +146.37% |
| Q2 2024 | 2024-06-30 | 0.38 | 0.23 | +162.60% |
| Q1 2024 | 2024-03-31 | 0.00 | −0.40 | — |
| Q4 2023 | 2023-12-31 | 0.34 | 0.11 | +45.32% |
| Q3 2023 | 2023-09-30 | 0.13 | −0.13 | −50.20% |
| Q2 2023 | 2023-06-30 | 0.14 | −0.14 | −49.19% |
| Q1 2023 | 2023-03-31 | 0.40 | 0.15 | +61.40% |
| Q4 2022 | 2022-12-31 | 0.24 | −0.31 | −56.62% |
| Q3 2022 | 2022-09-30 | 0.26 | 0.05 | +20.72% |
| Q2 2022 | 2022-06-30 | 0.28 | 0.04 | +18.34% |
| Q1 2022 | 2022-03-31 | 0.25 | 0.10 | +70.94% |
| Q4 2021 | 2021-12-31 | 0.55 | 0.31 | +128.80% |
| Q3 2021 | 2021-09-30 | 0.22 | 0.03 | +15.32% |
| Q2 2021 | 2021-06-30 | 0.24 | 0.13 | +117.88% |
| Q1 2021 | 2021-03-31 | 0.14 | 0.05 | +55.14% |
| Q4 2020 | 2020-12-31 | 0.24 | 0.13 | +118.93% |
| Q3 2020 | 2020-09-30 | 0.19 | 0.12 | +167.66% |
| Q2 2020 | 2020-06-30 | 0.11 | −0.71 | −86.61% |
| Q1 2020 | 2020-03-31 | 0.09 | −8.07 | −98.86% |
| Q4 2019 | 2019-12-31 | 0.11 | −5.47 | −98.05% |
| Q3 2019 | 2019-09-30 | 0.07 | −5.25 | −98.67% |
| Q2 2019 | 2019-06-30 | 0.81 | −2.17 | −72.69% |
| Q1 2019 | 2019-03-31 | 8.16 | — | — |
| Q4 2018 | 2018-12-31 | 5.58 | — | — |
| Q3 2018 | 2018-09-30 | 5.32 | — | — |
| Q2 2018 | 2018-06-30 | 2.98 | — | — |
| Q4 2016 | 2016-12-31 | 0.19 | −1.14 | −86.00% |
| Q1 2016 | 2016-03-31 | 0.05 | — | — |
| Q4 2015 | 2015-12-31 | 1.32 | 1.13 | +600.65% |
| Q3 2015 | 2015-09-30 | 0.08 | — | — |
| Q2 2015 | 2015-06-30 | 0.58 | — | — |
| Q4 2014 | 2014-12-31 | 0.19 | −0.07 | −25.85% |
| Q4 2013 | 2013-12-31 | 0.25 | — | — |
Over the last five fiscal years, BioCorRx's debt-to-assets ratio decreased from 0.24 to 0.07, a change of −0.16. The latest reported quarter, Q2 2026, shows 0.07.
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioCorRx source filings ↗